Mastronardi Luciano, Roperto Raffaelino, Cacciotti Guglielmo, Calvosa Francesco
Department of Neurosurgery, San Filippo Neri Hospital of Roma, via Martinotti 20 Roma, Italy, Roma 00135, Italy.
J Neurol Surg A Cent Eur Neurosurg. 2018 Nov;79(6):496-501. doi: 10.1055/s-0038-1642008. Epub 2018 Jun 14.
Anterior cervical fusion (ACF) with autologous bone was reported > 50 years ago. The continuous development of materials with elastic properties close to that of the cortical bone improves induction of osteogenesis and simplifies the technique of interbody fusion. To determine the safety and efficiency of stand-alone trabecular metal (TM) (or porous tantalum) cages for ACF, we performed a retrospective analysis of 88 consecutive patients with one-level or two-level degenerative disk disease (DDD) causing cervical myelopathy treated by interbody fusion with stand-alone TM cages.
During a 65-month period, 88 consecutive patients had ACF at 105 levels between C3 and C7. All surgeries involved one- or two-segmental DDD producing mild or severe cervical spine myelopathy, in 31 patients (35.2%), associated with unilateral or bilateral radiculopathy. We implanted all disk spaces with unfilled TM trapezoidal cages (Zimmer Biomet Spine, Broomfield, Colorado, United States).
At a mean follow-up of 31 months (range: 12-65 months), 95.4% of patients had a good to excellent outcome, with subjective and objective improvement of myelopathy; the result was fair in two and poor in two other patients. Radicular pain and/or any deficits disappeared in 84 patients (95.4%) complaining of preoperative myeloradiculopathy. The fusion rate was 68.2% at 6 months and 100% at 1 year. Device fragmentation was never observed. In two cases, a second operation with removal of TM cages, corpectomy, expansion cages, and plating was necessary.
TM cages appear to be safe and efficient for ACF in DDD patients with myelopathy. To confirm our preliminary impressions, larger studies with long-term follow-up are necessary.
自体骨前路颈椎融合术(ACF)早在50多年前就有报道。弹性性能接近皮质骨的材料不断发展,改善了骨生成诱导并简化了椎间融合技术。为了确定单独使用小梁金属(TM)(或多孔钽)椎间融合器进行ACF的安全性和有效性,我们对88例连续的单节段或双节段退行性椎间盘疾病(DDD)导致的颈椎脊髓病患者进行了回顾性分析,这些患者均接受了单独使用TM椎间融合器的椎间融合术治疗。
在65个月的时间里,88例连续患者在C3至C7之间的105个节段进行了ACF。所有手术均涉及单节段或双节段DDD,导致轻度或重度颈椎脊髓病,31例患者(35.2%)伴有单侧或双侧神经根病。我们在所有椎间盘间隙植入了未填充的TM梯形椎间融合器(美国科罗拉多州布鲁姆菲尔德市的齐默·生物马特脊柱公司生产)。
平均随访31个月(范围:12 - 65个月),95.4%的患者预后良好至优秀,脊髓病有主观和客观改善;2例患者结果一般,另外2例患者结果较差。84例术前有脊髓神经根病的患者,其神经根性疼痛和/或任何神经功能缺损消失(95.4%)。6个月时融合率为68.2%,1年时为100%。从未观察到器械碎裂。有2例患者需要进行第二次手术,取出TM椎间融合器、椎体次全切除术、使用撑开式椎间融合器并进行钢板固定。
对于患有脊髓病的DDD患者,TM椎间融合器用于ACF似乎是安全有效的。为了证实我们的初步印象,有必要进行更大规模的长期随访研究。